To assess whether clinicians interpret GBS detected by the BIOFIRE Pneumonia Panel as a pathogen implicated in pneumonia, considering its potential role as a colonizer.
Key Findings:
GBS was considered a pneumonia pathogen in 47.7% of cases and a nonpathogen in 52.3%.
ID consultation was performed in 33.0% of cases, with GBS considered a pathogen in 30.6% of those.
Common comorbid conditions included pulmonary, gastrointestinal, neurologic, and cardiovascular diseases.
Endotracheal intubation rates were similar in both groups (51.9% vs 50.9%).
In-hospital mortality was numerically higher in the pathogen group (21.2% vs 14.0%; P = .33).
76.1% of GBS detections had codetected microorganisms, primarily Staphylococcus aureus.
Only 10.2% of BF-PP GBS-positive specimens were culture positive for GBS.
Interpretation:
While GBS is detected in pneumonia cases, its clinical significance remains uncertain, often coexisting with other pathogens, indicating a need for careful interpretation.
Limitations:
Retrospective design may introduce bias and affect data accuracy.
Interpretation of GBS as a pathogen may vary among clinicians.
Limited generalizability due to single-center study.
Conclusion:
The detection of GBS in respiratory specimens does not definitively indicate its role as a pneumonia pathogen, highlighting the need for careful clinical interpretation and consideration of other potential pathogens.
